BRIEF: Aphria’s Malta-Based ASG Pharma Receives First Malta Import License

New York, NY — June 21, 2018 — /D.M.O. Newswire/ — Aphria Inc.  (TSX:APH) (OTC:APHQF) (FRA:10E) announced that its Malta-based subsidiary ASG Pharma is the recipient of the first import license for medical cannabis issued by the Malta Medicines Authority.

Here’s What You Need to Know

• Valletta, Malta-based ASG Pharma Ltd. has been a subsidiary of Aphria since February 26th, 2018.
• Malta’s legislative and regulatory standards are extremely rigorous, making the license extremely valuable.
• The license will allow ASG to import medical cannabis for analytical testing and research.
• This is an important step that will enable ASG to become a cornerstone in testing, research and development of medical cannabis in Europe.
• ASG currently operates a high-capacity EU GMP-certified lab.
• ASG is currently undergoing a multi-million-euro upgrade of its processing and manufacturing capabilities that will result in its ability to process, extract package and label pharmaceutical-grade medical cannabis and cannabis derivative products.
• Aphria intends to use the EU GMP-certified lab in Malta as a long-term processing, manufacturing and distribution hub for the entire European continent.